Pharmacogenomics Market Size, Segment Analysis, Top Leaders, and Demand Forecast Report 2030

The size of the pharmacogenomics market was approximately $5,527.2 million in the year 2021, and it will advance at a 7.4% growth rate in the years to come and reach $10,505.3 million in 2030.

The growth of the industry is because of the growing occurrence of infectious sicknesses and numerous types of cancer, increasing acceptance of tailored medicine, a shift from reaction to deterrence worldwide, increasing rate of ADRs, and growing use of pharmacogenomics in the finding and expansion of medicines.

Download sample copy of this report: https://www.psmarketresearch.com/market-analysis/pharmacogenomics-market/report-sample

In the year 2021, genotyping services had the largest share in the pharmacogenomics market, of about 45%. This is mostly because of the recommendations of health providers globally for obtaining individual genomic profiles, to cater to the regularly evolving demands of healthcare. Moreover, targeted genotyping knowhow is used by the majority of pharmacogenetic testing labs to clinically screen for specific alternatives with renowned interaction of drug-genes.

Within the application segment, oncology contributed about $2,682.2 million in revenue in the year 2021 in the pharmacogenomics market. This tendency will stay this way in the near future as well because of the quick acceptance of pharmacogenomics in the devel opment of drugs, particularly in progressive economies; the high occurrence of diverse kinds of cancers, and the increasing requirement for biologics and the drugs which are based on monoclonal antibodies for the treatment of tumors. Moreover, cancer pharmacogenomics has aided a number of key advancements in cancer treatment. For example, a chemotherapeutic drug Irinotecan is used for the treatment of colon cancer.

ADRs are undesirable effects of a specific medication happening at the time of clinical use. Furthermore, they can be long-lasting, therefore harmfully affecting the life of a patient. In life-threatening cases, ADRs can cause illness and mortality. The growing volume of medicines in the pharmacogenomics market, rising elderly population, and thriving inclination toward polypharmacy are steadily pushing the occurrence of ADRs worldwide. As per the FDA, in the year 2020, in the U.S., 2.22 million ADRs were reported, 1.18 million out of which were serious and 0.19 million led to death.

Make inquiry before purchase of this report: https://www.psmarketresearch.com/send-enquiry?enquiry-url=pharmacogenomics-market

The PCR technology had over 45% market share in the year 2021. This is chiefly because a small sample is used by PCR for analysis, for detecting microbial agents, and the procedure consumes about 4-8 hours, which is about 3 times faster than further procedures. Moreover, multiplex PCR is a kind of PCR that may amplify more than a few DNA sequences in one reaction. It is normally used to identify a diversity of antibiotic genes. Moreover, PCR has established higher positivity and sensitivity rates than strains and culture for both bacteria and fungi.

Key Players in Pharmacogenomics Market Are:
• Thermo Fisher Scientific Inc.
• F. Hoffmann-La Roche Ltd.
• Myriad Genetics Inc.
• Exact Sciences Corporation
• Mesa Laboratories Inc.
• 23andMe Inc.
• Laboratory Corporation of America Holdings
• QIAGEN N.V.
• Admera Health LLC
• Abbott Laboratories

North America is the leader in the pharmacogenomics market, and the industry in the region will grow at a rate of 7% in the coming years. The surge in the adoption of pharmacogenomic practices in the region is driven by government initiatives for integrating targeted medicine approaches in the typical healthcare system. Furthermore, the U.S. FDA and the CLIA have been at the lead in the expansion of effective and apt policies and guidelines with the purpose of propelling the acceptance of pharmacogenomic tests by end-users.

There has been an increase in the requirement for pharmacogenomics due to the increasing prevalence of many infectious diseases.

Browse full report at: https://www.psmarketresearch.com/market-analysis/pharmacogenomics-market

Pharmacogenomics Market Size Breakdown by Segment

By Service
• Genotyping
• SNP Identification
• Pharmacogenetic Testing
By Technology
• Polymerase Chain Reaction (PCR)
• Microarray
• Sequencing
By Application
• Oncology
• Infectious Diseases
• Neurology
• Cardiovascular Diseases
By End User
• Research Organizations
• Pharmaceutical Companies
• Diagnostic Centers
Regional Analysis
• North America
o U.S.
o Canada
• Europe
o Germany
o France
o U.K.
o Italy
o Spain
• Asia-Pacific (APAC)
o China
o India
o Japan
• Latin America (LATAM)
o Brazil
o Mexico
• Middle East and Africa (MEA)
o Saudi Arabia
o South Africa

Contact:
Chandra Mohan
AVP - Business Development
Phone: +1-347-960-6455
Email: enquiry@psmarketresearch.com
Web: https://www.psmarketresearch.com
Blog: https://www.psmarketresearch.com/blogs

About P&S Intelligence

P&S Intelligence offers custom and syndicated market research and consulting services to clients across the globe. Our team of young and dynamic researchers, guided by mentors with years of experience, create data-rich reports tailored to the needs of MNCs as well as startups and SMEs. We remain in a perennial quest to offer exhaustive insights into every aspect of the market, allowing businesses of all sizes to seize even the smallest of opportunities and tackle even the biggest of challenges.

This release was published on openPR.